Form 4: Acadia Pharmaceuticals Executive James Kihara Reports Stock Option and Restricted Stock Unit Grants

James Kihara, Principal Accounting Officer of Acadia Pharmaceuticals, reports the acquisition of stock options and restricted stock units.

Summary

• On March 25, 2024, James Kihara, Principal Accounting Officer of Acadia Pharmaceuticals, was granted stock options for 13,964 shares and 8,568 restricted stock units (RSUs).
• The stock options have an exercise price of $17.84 per share.
• 25% of the stock options will vest on March 25, 2025, with the remaining shares vesting in 36 equal monthly installments thereafter.
• The restricted stock units vest in four equal annual installments beginning March 25, 2025.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive as it reflects standard executive compensation practices, incentivizing performance and aligning interests.

Positives

• The granting of stock options and RSUs aligns the executive's interests with those of the shareholders.
• The vesting schedules incentivize long-term performance and retention.

Industry Context

Stock options and restricted stock units are common forms of executive compensation in the pharmaceutical industry, used to incentivize performance and align management interests with shareholder value.

Comparison to Industry Standards

• Stock option grants are a standard component of compensation packages for executives in publicly traded companies, particularly in the biotech and pharmaceutical sectors.
• Companies like Biogen, Amgen, and Gilead Sciences also utilize stock options and RSUs to incentivize their executives.
• The vesting schedules described are typical, with vesting periods ranging from three to four years.

Stakeholder Impact

• Shareholders may view the grants positively as they incentivize management to improve company performance.
• Employees may see this as a positive sign of the company investing in its leadership.

Key Dates